112 related articles for article (PubMed ID: 20204554)
21. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
Kim HJ; Cui X; Hilsenbeck SG; Lee AV
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
[TBL] [Abstract][Full Text] [Related]
22. Clinical and biological characteristics of breast cancer.
Kocic B; Filipovic S; Petrovic B; Mijalkovic D; Rancic N; Poultsidi A
J BUON; 2010; 15(4):660-7. PubMed ID: 21229626
[TBL] [Abstract][Full Text] [Related]
23. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
24. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
26. Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related.
Neven P; Pochet N; Drijkoningen M; Amant F; De Smet F; Paridaens R; Christiaens MR; Vergote I
J Clin Oncol; 2006 Jun; 24(16):2595; author reply 2595-7. PubMed ID: 16735717
[No Abstract] [Full Text] [Related]
27. Breast carcinoma with chondroid differentiation: a clinicopathologic study of 21 triple negative (ER-, PR-, Her2/neu-) cases.
Gwin K; Wheeler DT; Bossuyt V; Tavassoli FA
Int J Surg Pathol; 2010 Feb; 18(1):27-35. PubMed ID: 19282292
[TBL] [Abstract][Full Text] [Related]
28. [Correlation analysis of vascular endothelial growth factor-C expression and clinicopathology in breast cancer].
Fu JM; Shi J; Zhou J
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov; 29(11):2266-8. PubMed ID: 19923084
[TBL] [Abstract][Full Text] [Related]
29. Flow cytometry: a new approach for the molecular profiling of breast cancer.
Lostumbo A; Mehta D; Setty S; Nunez R
Exp Mol Pathol; 2006 Feb; 80(1):46-53. PubMed ID: 16271361
[TBL] [Abstract][Full Text] [Related]
30. Expression of epidermal growth factor receptors (EGFR) on breast carcinomas in relation to growth fractions, estrogen receptor status and morphological criteria. An immunohistochemical study.
Wrba F; Reiner A; Ritzinger E; Holzner JH; Reiner G
Pathol Res Pract; 1988 Feb; 183(1):25-9. PubMed ID: 3362749
[TBL] [Abstract][Full Text] [Related]
31. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
[TBL] [Abstract][Full Text] [Related]
32. [Changing behavior of estrogen and progesterone receptors with metastasis or recurrence of breast cancer].
Morimoto K; Koh M; Yamamoto A; Tamura K; Yamamoto K; Yamamoto K; Suehiro S
Gan To Kagaku Ryoho; 2006 Jul; 33(7):925-9. PubMed ID: 16835481
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical expression and significance of epidermal growth factor receptor (EGFR) in breast cancer.
Meche A; Cîmpean AM; Raica M
Rom J Morphol Embryol; 2009; 50(2):217-21. PubMed ID: 19434314
[TBL] [Abstract][Full Text] [Related]
34. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression.
Miller DL; el-Ashry D; Cheville AL; Liu Y; McLeskey SW; Kern FG
Cell Growth Differ; 1994 Dec; 5(12):1263-74. PubMed ID: 7696175
[TBL] [Abstract][Full Text] [Related]
35. Expression of neu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer. Correlation with clinicopathologic parameters.
Lundy J; Schuss A; Stanick D; McCormack ES; Kramer S; Sorvillo JM
Am J Pathol; 1991 Jun; 138(6):1527-34. PubMed ID: 1711294
[TBL] [Abstract][Full Text] [Related]
36. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of scoring system based on histological heterogeneity of invasive ductal carcinoma for node-negative breast cancer patients.
Kurosumi M; Tabei T; Inoue K; Takei H; Ninomiya J; Naganuma R; Suemasu K; Higashi Y; Tsuchiya E
Oncol Rep; 2003; 10(4):833-7. PubMed ID: 12792731
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
Rydén L; Jirström K; Haglund M; Stål O; Fernö M
Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
[TBL] [Abstract][Full Text] [Related]
39. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
40. Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survival and clinicopathological findings.
Molaei M; Pejhan S; Nayer BN; Moradi A; Ghiasi S; Zali MR
Eur J Gastroenterol Hepatol; 2009 Mar; 21(3):289-93. PubMed ID: 19279475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
